4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on the Anaplastic Astrocytoma Pipeline Drugs to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Anaplastic Astrocytoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 92 ongoing clinical trials involving Anaplastic Astrocytoma
Of the 92 trials,37 trials are in Phase I
Furthermore, 23 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Anaplastic Astrocytoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Anaplastic Astrocytoma, an Oncology indication. The highest number of ongoing clinical trials involving Anaplastic Astrocytoma is in North America. Europe and Asia-Pacific are among some of the other prominent regions involved in Anaplastic Astrocytoma-related drug trials.

National Cancer Institute US: The leading ongoing Anaplastic Astrocytoma-related clinical trials sponsor

National Cancer Institute US, the United States of America-based government agency, is the top sponsor for Anaplastic Astrocytoma-related ongoing clinical trials.

University of Texas MD Anderson Cancer Center, European Organization for Research and Treatment of Cancer, Dana-Farber/Harvard Cancer Center, Northwell Health Inc, and University of Alabama at Birmingham are a few other notable sponsors involving Anaplastic Astrocytoma.

A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Anaplastic Astrocytoma

Temozolomide (Temodar, Temodal, Astromide) is the sole key marketed drug involving Anaplastic Astrocytoma.

Temozolomide (Temodar, Temodal, Astromide) is an alkylating agent that acts as an antineoplastic agent. It functions via the DNA Synthesis Inhibitor mechanism of action. It is formulated as hard gelatin capsules for the oral route of administration and lyophilized powder for the solution for the intravenous route of administration. Temozolomide is indicated for the treatment of glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment. Temozolomide was first approved in 1998 and is marketed globally including the US, the UK, France, Germany, China, and Japan by several prominent pharma giants including Merck Sharp & Dohme Corp.

Explore the latest trends and actionable insights on the Anaplastic Astrocytoma Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Anaplastic Astrocytoma Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Visit Report Store